事实证据 1
暂无可公开的证据摘要。
BioPharma Dive · 2026-11-02 22:34
查看证据
- 媒体BioPharma Dive2026-11-02 22:34查看来源
公司
Formycon AG
Formycon AG 的结构
Formycon AG
公司
4 个关联
同行竞争与合作
下游客户
约束监管与敞口
关系出现时间
Formycon AG公司 · 4 个关联
第 1 层下游客户1
同行竞争与合作2
约束监管与敞口1
在关系网络中的位置
第 6837 位，共 75986 个前 9%本周下降 2203 位
3 条直接关系
所在群组共 1112 个紧密关联的对象，核心是
按有证据的公开关系计算，每天更新。
关系
箭头表示关系方向，可按业务类别筛选。
- 产品 · FYB206证据 1事实90%
查看证据
- 公司披露PR Newswire news releases2026-10-13 21:30
Formycon is responsible for completing development, preparing and filing the regulatory dossiers, and supplying the product.
查看来源
- 地区 · Martinsried证据 1事实90%
查看证据
- 公司披露PR Newswire news releases2026-10-13 21:30
Formycon AG is a listed, independent developer of biosimilars based in Martinsried, one of the leading life science locations in Europe, just outside Munich, Germany.
查看来源
- 事实90%
查看证据
- 公司披露PR Newswire news releases2026-10-13 21:30
Three Formycon biosimilars are approved in ophthalmology and immunology and are marketed worldwide through commercialization partners.
查看来源
- 事实90%
- 事实90%
查看证据
- 公司披露PR Newswire news releases2026-10-13 21:30
In December 2025, Formycon and Zydus had entered into an exclusive licensing and supply agreement for FYB206 in the United States and Canada.
查看来源
显示第 1 至 5 条，共 5 条
结论
结合来源阅读结论，展开条目查看证据。
事实证据 1
Formycon AG is a listed, independent developer of biosimilars based in Martinsried, one of the leading life science locations in Europe, just outside Munich, Germany.
PR Newswire news releases · 2026-10-13 21:30
查看证据
- 公司披露PR Newswire news releases2026-10-13 21:30
Formycon AG is a listed, independent developer of biosimilars based in Martinsried, one of the leading life science locations in Europe, just outside Munich, Germany.
查看来源
事实证据 1
employees200 employees
Its 200 employees from 27 countries cover the entire development chain, from laboratory analysis through manufacturing and clinical testing to the documents for approval.
PR Newswire news releases · 2026-10-13 21:30
查看证据
- 公司披露PR Newswire news releases2026-10-13 21:30
Its 200 employees from 27 countries cover the entire development chain, from laboratory analysis through manufacturing and clinical testing to the documents for approval.
查看来源
事实证据 1
approved biosimilars3 biosimilars
Three Formycon biosimilars are approved in ophthalmology and immunology and are marketed worldwide through commercialization partners.
PR Newswire news releases · 2026-10-13 21:30
查看证据
- 公司披露PR Newswire news releases2026-10-13 21:30
Three Formycon biosimilars are approved in ophthalmology and immunology and are marketed worldwide through commercialization partners.
查看来源
事实证据 1
Three Formycon biosimilars are approved in ophthalmology and immunology and are marketed worldwide through commercialization partners.
PR Newswire news releases · 2026-10-13 21:30
查看证据
- 公司披露PR Newswire news releases2026-10-13 21:30
Three Formycon biosimilars are approved in ophthalmology and immunology and are marketed worldwide through commercialization partners.
查看来源
事实证据 1
供应给FYB206
Formycon is responsible for completing development, preparing and filing the regulatory dossiers, and supplying the product.
PR Newswire news releases · 2026-10-13 21:30
查看证据
- 公司披露PR Newswire news releases2026-10-13 21:30
Formycon is responsible for completing development, preparing and filing the regulatory dossiers, and supplying the product.
查看来源
显示第 1 至 6 条，共 8 条
市场与估值
估值数据需要 Pro 或 Research。
升级到 Pro 解锁推荐一个值得监测的页面
这家公司有哪些页面值得盯着，比如价格、更新日志、条款或招聘页？推荐给我们。每条推荐都有人看；收录后，这个页面会为所有读者一起监测，并且只有连续两次抓取一致才算一次变化。
暂无: 公司信号 · 财务数据 · 披露文件 · 据点 · 业绩指引